RhumbLine Advisers
DSGN icon

RhumbLine Advisers’s Design Therapeutics DSGN Stock Holding History

RhumbLine Advisers’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$552K Buy
38,132
+3,272
+9% +$40.8K ﹤0.01% 2697
2026
Q1 		$371K Buy
34,860
+82
+0.2% +$830 ﹤0.01% 2792
2025
Q4 		$326K Sell
34,778
-11,556
-25% -$90.5K ﹤0.01% 2921
2025
Q3 		$349K Sell
46,334
-1,983
-4% -$9.93K ﹤0.01% 2903
2025
Q2 		$163K Buy
48,317
+1,948
+4% +$7.29K ﹤0.01% 3337
2025
Q1 		$179K Sell
46,369
-6,563
-12% -$31.3K ﹤0.01% 3165
2024
Q4 		$327K Buy
52,932
+2,365
+5% +$13.7K ﹤0.01% 2943
2024
Q3 		$272K Sell
50,567
-2,500
-5% -$11.8K ﹤0.01% 3073
2024
Q2 		$178K Buy
53,067
+615
+1% +$2.4K ﹤0.01% 3292
2024
Q1 		$211K Buy
52,452
+1,588
+3% +$4.24K ﹤0.01% 3148
2023
Q4 		$135K Sell
50,864
-1,612
-3% -$3.69K ﹤0.01% 3351
2023
Q3 		$124K Buy
52,476
+886
+2% +$4.13K ﹤0.01% 3383
2023
Q2 		$325K Sell
51,590
-98
-0.2% -$600 ﹤0.01% 2954
2023
Q1 		$298K Buy
51,688
+72
+0.1% +$539 ﹤0.01% 2618
2022
Q4 		$530K Sell
51,616
-156
-0.3% -$2.11K ﹤0.01% 2437
2022
Q3 		$866K Buy
51,772
+3,544
+7% +$70.5K ﹤0.01% 2221
2022
Q2 		$675K Buy
48,228
+19,944
+71% +$269K ﹤0.01% 2335
2022
Q1 		$457K Buy
28,284
+4,995
+21% +$76.5K ﹤0.01% 2459
2021
Q4 		$499K Buy
23,289
+12,700
+120% +$218K ﹤0.01% 2510
2021
Q3 		$156K Buy
+10,589
New +$176K ﹤0.01% 2944

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RhumbLine Advisers's DSGN Position: Q2 2026 in Review

RhumbLine Advisers increased its Design Therapeutics (DSGN) stake by 9.4% in Q2 2026, buying an estimated $40.8K and bringing the position to 38,132 shares worth $552K. The position accounts for ﹤0.01% of the portfolio, ranked #2697.

RhumbLine Advisers first reported a position in DSGN in Q3 2021 and has held it in 20 quarters since. The position peaked at $866K in Q3 2022. 137 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • RhumbLine Advisers held 38,132 shares of Design Therapeutics worth $552K as of Q2 2026.
  • RhumbLine Advisers bought 3,272 Design Therapeutics shares in Q2 2026, an estimated $40.8K.
  • Design Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2697 holding.
  • RhumbLine Advisers first reported a position in Design Therapeutics in Q3 2021 and has held it in 20 quarters since.
  • RhumbLine Advisers's Design Therapeutics position peaked at $866K in Q3 2022.
  • 137 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.